Table 5.

Primary tumors differentiated based on combined immunostaining of the marker for proliferation Ki67 and prostate specific antigen (PSA), in relation to the transcriptomic metastasis subtypes MetA-C of paired bone metastases.

	Ki67 Low, PSA High a	Ki67 High, PSA Low a	Others a
	n = 22 (%)	n = 22	n = 26
MetA b, n = 48	20 (91)	8 (36)	20 (77)
MetB b, n = 11	0 (0)	8 (36)	3 (12)
MetC b, n = 11	2 (9)	6 (27)	3 (12)

^a A combinatory immunoreactivity score for Ki67 and PSA constructed based on the median values (13% and 8%, respectively) stratified primary tumors into 3 groups: “low Ki67, high PSA”, “high Ki67, low PSA”, and “Others”. ^b Fractions of the metastasis subtypes MetA-C were estimated based on expression levels of 157 MetA-C-associated genes, as previously described [4], and each sample was classified based on its dominant MetA-C fraction.